Clinical Trials Logo

Asthma clinical trials

View clinical trials related to Asthma.

Filter by:

NCT ID: NCT02725242 Completed - Asthma Clinical Trials

Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma

Start date: March 2016
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy of Once-daily Budesonide/formoterol Turbuhaler 160/4.5 µg/d in the period of step down in well controlled asthmatic patient.

NCT ID: NCT02725008 Completed - Asthma Clinical Trials

Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation

R2D2
Start date: November 2015
Phase: Phase 3
Study type: Interventional

Comparing one versus two doses of oral dexamethasone for the treatment of asthma in the pediatric emergency department.

NCT ID: NCT02724657 Completed - Asthma Clinical Trials

Buteyko Method for Asthmatic Children With Mouth Breathing

Start date: March 2016
Phase: N/A
Study type: Interventional

To assess the effectiveness of the Buteyko method as an adjunct therapy in the treatment of asthmatic children with mouth breathing.

NCT ID: NCT02720380 Completed - Asthma Clinical Trials

Buteyko Method for Children With Asthma

Start date: July 2015
Phase: N/A
Study type: Interventional

This study has the aim to assess the effectiveness of the Buteyko method as an adjunct therapy in the treatment of children with asthma.

NCT ID: NCT02720081 Completed - Asthma Clinical Trials

Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)

Start date: May 11, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to compare the safety, tolerability, and efficacy of adding MK-1029 to montelukast in adults with persistent asthma that is uncontrolled while receiving montelukast alone. Participants will have a specific genetic marker for clinical efficacy of MK-1029. The primary hypothesis is that when added to montelukast, treatment with MK-1029 is superior to placebo, as demonstrated by an increase in forced expiratory volume in one second (FEV1), measured as the average change from baseline at the end of Week 4 and Week 6 of treatment.

NCT ID: NCT02719899 Completed - Asthma Clinical Trials

Effect of Fasting and Refeeding on T-cell Fate

Start date: April 18, 2016
Phase:
Study type: Observational

Background: Researchers want to better understand the body s immune response to calorie restriction. To do this, they are asking healthy volunteers to fast for 24 hours. Researchers will test immune response before and after fasting. Objectives: To explore the benefits of calorie restriction on immune health. Eligibility: Healthy volunteers ages 21 to 37 with a body mass index between 22 and 29. Design: Participants will be screened with medical history, physical exam, and blood tests. Participants will visit NIH after an overnight fast. Their baseline immune response will be taken. They will give blood and urine samples. Then they will be given breakfast. This visit will take about 2 hours. Participants will fast (not eat or drink anything except water) for the next 24 hours. They will return to NIH the next morning. Their immune response will be taken. They will give blood and urine samples. Then they will be given breakfast. Their immune response will be taken 3 hours later. They will give a blood sample. This visit will take about 4 hours.

NCT ID: NCT02719379 Completed - Asthma Clinical Trials

Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma

Start date: April 2016
Phase: Phase 1
Study type: Interventional

Advisory Committee for Immunization Practices (ACIP) from the Centers for Disease Control (CDC) recommends that children (6-18 years) and adults (≥19 years old) with chronic lung condition such as asthma or cigarette smoking be vaccinated with Pneumococcal vaccine (PPSV23). The purpose of this study is to increase awareness of vaccination to late adolescents with asthma and smokers (social aspect of study), and to recommend vaccination (which is the clinical aspect). Individuals who agree to receiving vaccine will be enrolled in research to determine whether late adolescents with and without asthma (smokers) have distinctive pneumococcal vaccine response patterns and whether such patterns are associated with subsequent variance in asthma outcomes.

NCT ID: NCT02719145 Completed - Asthma Clinical Trials

Circulating Micro RNAs Expression in Egyptian Bronchial Asthma and COPD Patients

Start date: October 2015
Phase:
Study type: Observational

This cross sectional study will be carried out on 30 subjects who will be recruited from the outpatient clinic of Chest Department, Tanta University Hospital. They will be classified into 3 groups: Group I: It will include 10 healthy volunteer subjects. Group II: It will include 10 asthmatic patients. Group III: It will include 10 COPD patients. miR-7, miR-20a, miR-21, miR-22, miR-145 and miR-155 will be measured in serum samples from all subjects

NCT ID: NCT02718339 Not yet recruiting - Asthma Clinical Trials

In-patient Asthma Counseling by Pulmonologist and Hospital Re-admission Rate

Start date: April 2016
Phase: N/A
Study type: Interventional

Prospective randomized clinical trial to assess the effect of in-hospital intensive counseling and follow-up vs. usual care, on re-admission rates of patients with Asthma. The study population will include asthma patients admitted to internal Medicine departments and medical ICU at Soroka University Medical Center, due to asthma exacerbation.

NCT ID: NCT02717689 Completed - Clinical trials for Severe Persistent Asthma

A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma

Start date: January 1, 2016
Phase: N/A
Study type: Interventional

This study explores if a composite biomarker strategy predicts exacerbation risk in patients with asthma on high dose inhaled corticosteroid (+/-long-acting beta agonist) treatment and to evaluate the utility of this composite score to facilitate personalised biomarker specific titration of corticosteroid therapy in this population.